Welcome : Guest

NANOBIOTECHNOLOGY - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Nanobiotechnology in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 79 companies including many key and niche players such as -

Ablynx NV
Arrowhead Pharmaceuticals, Inc.
Avadel Pharmaceuticals plc
CaPtivate Pharmaceuticals LLC
Celgene Corporation

Click here to request a full list of companies covered in the report...

Code: MCP-1476
Price: $4950
Companies: 79
Pages: 267
Date: January 2017
Market Data Tables: 19
 



TABLE OF CONTENTS


  NANOBIOTECHNOLOGY (Complete Report) Pages : 267   | $4950

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   A Curtain Raiser.....II-11$100
   Nanobiotechnology – The Next Big Thing.....II-22$200
   An Insight into the Global Nanobiotechnology Market.....II-4
Major Market Drivers.....II-4
1$100
   Where Conventional Molecular Science Falls Short Nanobio Steps In.....II-51$100
   Nanotechnology Revolutionizes Pharmaceuticals & Healthcare Sector.....II-6
Nanomedicine Market to Achieve Phenomenal Growth.....II-6
1$100
   Opportunities Galore for Nanomedicine.....II-71$100
   Drug Delivery – A Promising Application Area for Nanotechnology.....II-8
Benefits Offered by Nanostructures in Drug Delivery.....II-8
1$100
   Select Key Requirements for Development of Advanced Drug Delivery Systems.....II-9
Nanotechnology Offers Huge Potential in Brain Disorder Treatment.....II-9
1$100
   High Demand for Nanobots and Nano Healthcare Devices.....II-10
Nanotechnology Gaining Prominence for Treatment of Cancer.....II-10
2$200
   Nanotechnology in Drug Delivery: A Specialized Market Opportunity.....II-121$100
   Commercialization of Nanotechnology-based Medical Products Gains Momentum.....II-131$100
   Nanodiagnostic Products to Witness Strong Demand Growth.....II-141$100
   Dendrimers Serve as a Base to Build Multifunctional Nanodevices.....II-15
Nanotechnology Rescues Poor Water Soluble Drugs from Abandonment.....II-15
1$100
   Huge Opportunities for Nanomaterials in the Medical Field.....II-161$100
   Commercial Opportunities in Healthcare Sector.....II-17
Future Possibilities.....II-17
1$100
   Global Market for Fullerenes – An Insight.....II-181$100
   Dawn Breaks on Nanobiotechnology.....II-19
Demystifying the Intriguing World of Nanobiotech.....II-19
1$100
   A Meeting Place of Medicine’s Best Solutions.....II-201$100
   Nanobiotechnology to Become Viable for All Drug Development Stages.....II-21
Nanoparticles: The Foundation of Nanobiotechnology.....II-21
1$100
   Improved Optical Properties and Stability of Nanoparticles.....II-22
Nanoemulsions.....II-22
1$100
   The Promise of Nanobiotechnology.....II-23
Biological Weaponries against Diseases Come in Small Packages.....II-23
1$100
   Proffered Benefits of Nanobiotechnology.....II-24
Opportunity & Beyond.....II-24
1$100
   Nanobiotechnology – Will it Live Up to the Expectations?.....II-251$100
   The Future of Nanobiotechnology: Shape of Things to Come.....II-26
Nanobiotechnology: The Outer Limits.....II-26
Futuristics: A Rumination.....II-26
1$100
   Conclusions.....II-271$100
   Competition in Select Segments.....II-28
Nanoparticles.....II-28
Nanotubes and Fullerenes.....II-28
Dendrimers.....II-28
Small and Medium-Sized Enterprises Spearheading Product Development.....II-28
1$100
   List of Select Approved Nanotechnology-based Drug Delivery Devices.....II-292$200
   Status of Select Nanoscale Drug Delivery Devices.....II-31
Collaborations Activity Picking Up Pace in Nanomedicine Domain.....II-31
1$100
   Present Status and Future Opportunities.....II-32
Outlook.....II-32
Developing Countries to Rise over the Horizon.....II-32
1$100
   Nanomaterials & Nanoparticles Witness Robust Activity.....II-33
Focus on Improved Performance to Bring New Manufacturing Methods for
  Nanomaterials.....II-33
Why Invest in Nanobiotechnology?.....II-33
1$100
   Private and Public Companies to Step Up Funding on Nanotechnology.....II-341$100
   United States Lead the Way in Government Funding.....II-35
Increasing Awareness on Technology to Drive Growth.....II-35
Demand for Novel Products to Push Up Growth.....II-35
1$100
   Nano-Enabled Drug Discovery Holds Tremendous Potential.....II-36
Consolidation Sharpens the Industry’s Edge.....II-36
The Regulatory Framework Evolves with the Technology.....II-36
Nanobiotechnology Gathers a Miniscule Share in Biotechnology Patents.....II-36
1$100
   Table 1: Percentage Breakdown of Number of Nanotechnology Publications in USPTO & EPO by Region/Country (2016) (includes corresponding Graph/Chart).....II-371$350
   Quantum Dot Patents Pose Legal Tangles.....II-38
Miniaturized Liquid Handling Becomes Progressive.....II-38
Trends in Nanotechnology Enabled Drug Delivery Systems.....II-38
Robust Growth on the Cards.....II-38
1$100
   Table 2: Global Nanomedicine Market by Application (2015): Percentage Breakdown of the Market for Drug Delivery, Implants, In vivo Diagnostics and In vitro Diagnostics (includes corresponding Graph/Chart).....II-39
Patent Expiries: A Key Driver.....II-39
1$350
   Nanotechnology Enabled Drug Delivery to Exhume Unused Drugs.....II-401$100
   Challenges.....II-411$100
   Commercial Exploration: A Treacherous Voyage.....II-42
Conventional Medicine to Contest Nanomedicine Adoption.....II-42
1$100
   Complexity of Nanotechnology Based Diagnostics and Treatment Methods Pose
  Challenges.....II-43
Nanomaterials Use: Weighed Down with Toxicity Concerns.....II-43
1$100
   Production Issues Continue to Plague Nanobiotech Industry.....II-44
Lack of De Facto Standards: A Challenge to Reckon With.....II-44
1$100
   Embroilment over Ethical Issues.....II-451$100
   Social Relevance.....II-461$100
   Economic Relevance.....II-471$100
   Industry Structure: A Quick Primer.....II-48
A Peek into the Regulatory Framework.....II-48
1$100
   United States.....II-49
Europe.....II-49
A Closer Look at Regional Nano Efforts.....II-49
United States: Unraveling the Country’s Edge.....II-49
1$100
   Table 3: Nanotechnology Patents in United States Patent and Trademark Office by Leading Countries: 2014-2016 (Sep) (includes corresponding Graph/Chart).....II-501$350
   Table 4: Nanotechnology Patents In European Patent Office by Leading Countries: 2014-2016 (Sep) (includes corresponding Graph/Chart).....II-511$350
   Table 5: Leading Countries in Terms of Number of Research Publications for Nanopolymeric Cardiac Scaffolds: 2005-2015 (June) (includes corresponding Graph/Chart).....II-52
Europe: Hot on the Heels of the US.....II-52
Germany.....II-52
1$350
   France.....II-53
United Kingdom.....II-53
Scandinavia.....II-53
Japan: A Noteworthy Region.....II-53
1$100
   A Primer.....II-54
Impact on Drug Delivery Systems.....II-54
1$100
   Benefits Offered.....II-55
Drug Encapsulation.....II-55
1$100
   High Level of Specificity.....II-56
Increase in Drug Solubility and Uptake.....II-56
Greater Usage Flexibility.....II-56
1$100
   Impact on Molecular Diagnostic Imaging.....II-57
Seeing the Unseen.....II-57
Impact on Therapeutics.....II-57
1$100
   Silver Nanoparticles as Effective Antimicrobial Agents.....II-58
Modern Day Nanomedicine: A Current Scenario.....II-58
1$100
   Nanomedicine: The Cynosure of All Eyes.....II-59
Applications of Nanomedicine.....II-59
Drug Delivery.....II-59
Drugs/ Therapy.....II-59
In Vivo Imaging.....II-59
1$100
   In Vitro Diagnostics.....II-60
Biomaterials.....II-60
Active Implants.....II-60
Drug Delivery Systems Epitomized by Nanomedicine.....II-60
Targeted NanoDrug Delivery & Release.....II-60
1$100
   Active and Passive Targeting Mechanisms in Drug Delivery.....II-61
Sustained and Pulsatile Release Mechanisms in Drug Delivery.....II-61
1$100
   A Peek into Potential Nanobio Enabled Drug Carriers.....II-62
Micelles.....II-62
Liposomes.....II-62
Dendrimers & Liquid Crystals.....II-62
1$100
   Nanoparticles.....II-63
Polymeric Nanoparticles.....II-63
Hydrogels.....II-63
Molecularly Imprinted Polymers.....II-63
1$100
   Microelectromechanical Systems (MEMS).....II-64
Nanosuspensions.....II-64
Fullerenes: A Platform for GenX Drug Delivery.....II-64
1$100
   Types of Nano-Based Drug Delivery Systems, Related Materials, and
  Structures.....II-65
Dynamics of Regenerative Medicine.....II-65
1$100
   Tissue Engineering and Restorations.....II-661$100
   Nanotechnology Enabled Diagnostics.....II-67
Promised Path Breaking Applications in Molecular Diagnostics & Imaging.....II-67
1$100
   In-Vitro Diagnostics.....II-681$100
   Nanoprobes & Implantable Devices in In-vivo Imaging.....II-69
Nanocomposites in Molecular Labeling & Diagnostics.....II-69
1$100
   Laboratory-on-a-Chip – A Revolutionary Technology in Biomolecular Detection.....II-70
Biosensors – Heralding New Opportunities in Molecular Diagnostics.....II-70
Nanobiosensors – A New Approach to Diagnostics Testing.....II-70
1$100
   Despite Huge Potential Key Hurdles Remain in Commercialization.....II-71
Magnetic Nanoparticles for Imaging Applications in MRI.....II-71
1$100
   Dendrimers Promise Milestone Applications in MRI.....II-72
Conclusions.....II-72
Gauging the Real World Impact of Nanobiotech on Cancer: A Case Study.....II-72
1$100
   Quantum Dots Cock a Snook at Traditional Anti-Body Labeling Agents.....II-731$100
   Chemotherapeutic Reengineering & Gene Therapy: New Treatment Regimes.....II-74
Futuristic Applications.....II-74
Bio-molecular Motors.....II-74
1$100
   Genetic and Tissue Engineering.....II-75
External Tissue Products.....II-75
Internal Tissue Implants.....II-75
1$100
   Dental and Bone Replacement.....II-76
Protein and Gene Analysis.....II-76
Nanorobot Therapeutics.....II-76
Laboratory-on-chip (LOC): A Portable Diagnostic Laboratory.....II-76
1$100
   Organs-On-A-Chip: Mimics Physiological Activities of Human Organs.....II-771$100
   Medical Diagnostic Sensors.....II-78
Nano Medical Devices – From Surgical Tools to Contact Lenses.....II-78
Nanoengineered Prosthetics.....II-78
Nanotubes – Potential Drug Delivery Vehicles.....II-78
2$200
   A*STAR Researchers Develop Nano-Sized Drug Molecules for Cancer Treatment.....II-801$100
   MIT Researchers Develop Nanodevice for Fighting Against Cancer Drug Resistance.....II-811$100
   Gold Nanotubes for Several Applications in the Fight Against Cancer.....II-82
IBM Research Working on NanoDLD Technology for Early Diagnosis of Cancer and other
  Diseases.....II-82
2$200
   Antifungal Bionanocomposites for Medical Devices.....II-84
DNA Nanostructures for Smart Diagnosis and Drug Delivery.....II-84
1$100
   Japanese Scientists Develop CNTs with Polymeric Coatings for Enhanced Drug
  Delivery.....II-85
1$100
   Other Noteworthy Nanotechnology Related Technology Innovations.....II-861$100
   Nanotechnology: An Introduction.....II-87
A Revolution in the Making.....II-87
1$100
   Nanobiotechnology: An Exposition.....II-88
Nanobiotechnology & Medicine.....II-88
Nanobiotechnology & Biofuels.....II-88
1$100
   Analysis of Major Technology Segments.....II-89
Nanomaterials.....II-89
Nanoparticles.....II-89
1$100
   Nanoparticles in Labeling or Bio Tagging.....II-90
Nanoparticles as Biomarkers.....II-90
Classification of Nanoparticles.....II-90
Solid Nanoparticles.....II-90
1$100
   Solid Lipid Nanoparticles.....II-91
Calcium Phosphate Nanoparticles.....II-91
Dendrimers.....II-91
1$100
   Cubosomes.....II-92
Nanocomposites.....II-92
Lamellar Nanocomposites.....II-92
1$100
   Nanostructured Materials and Membranes.....II-93
Quantum Dots.....II-93
Nanotubes and Fullerenes.....II-93
Fullerenes.....II-93
1$100
   Nanotubes.....II-94
Carbon Nanotubes (CNTs).....II-94
Other Nanomaterials.....II-94
Nanoshells.....II-94
Nanohorns.....II-94
1$100
   Nanocapsules.....II-95
Nanodevices.....II-95
Nanotools.....II-95
Select Nanotools.....II-95
Atomic Force Microscopes.....II-95
1$100
   Hot Embossing Lithography.....II-96
Dip-Pen Nanolithography.....II-96
Nanotechnology for Diseases Treatment.....II-96
Cancer.....II-96
1$100
   Parkinson’s Disease.....II-97
Alzheimer’s Disease.....II-97
Tuberculosis.....II-97
1$100
   Dentistry.....II-98
Ophthalmology.....II-98
Surgery.....II-98
1$100
   Cornell's Nanobiotechnology Center (USA).....II-99
Institute of Bioengineering and Nanotechnology (Singapore).....II-99
Michigan Nanotechnology Institute for Medicine and Biological Sciences (MNIMBS)
  (USA).....II-99
1$100
   The Tyndall National Institute (Ireland).....II-1001$100
   Vectura Group Inks Merger Agreement with Skyepharma.....II-101
Flamel Technologies to Merge with Avadel Pharmaceuticals.....II-101
Pfizer to Acquire BIND Therapeutics Assets.....II-101
Janssen Sciences Ireland Enters into Collaboration with ViiV Healthcare.....II-101
Tekna Holdings Canada Inks Agreement with National Research Council of Canada.....II-101
Roche and BioMed X Sign a Collaboration Agreement.....II-101
1$100
   Ablynx Enters into Exclusive Research Collaboration with Genzyme.....II-102
Pfizer Exercises Option to Develop and Commercialize Accurin.....II-102
BIND Therapeutics Inks Joint Research and Development Agreement with Merck.....II-102
1$100
   Ablynx NV (Belgium).....II-103
Arrowhead Pharmaceuticals, Inc. (USA).....II-103
Avadel Pharmaceuticals plc (Ireland).....II-103
1$100
   CaPtivate Pharmaceuticals LLC (USA).....II-104
Celgene Corporation (USA).....II-104
1$100
   ELITechGroup (France).....II-105
GlaxoSmithKline Plc. (UK).....II-105
1$100
   Johnson & Johnson (USA).....II-106
Merck & Co., Inc. (USA).....II-106
1$100
   NanoBio® Corporation (USA).....II-107
Nanophase Technologies Corporation (USA).....II-107
1$100
   pSivida Corp. (USA).....II-108
Sigma-Aldrich Corp. (USA).....II-108
1$100
   Starpharma Holdings Ltd. (Australia).....II-109
Vectura Group plc (UK).....II-109
1$100
   Table 6: World Recent Past, Current & Future Analysis for Nanobiotechnology by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....II-1101$350
   Table 7: World Historic Review for Nanobiotechnology by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....II-1111$350
   Table 8: World 14-Year Perspective for Nanobiotechnology by Geographic Region - Percentage Breakdown of Revenues for US, Japan, Europe, and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....II-1121$350
   A. Market Analysis.....III-1
Industry Overview.....III-1
1$75
   Academic Research Lending Strength to Creation of Novel Nanobiotech Products.....III-2
Table 9: Number of Drugs Approved by FDA: 2001-2016 (includes corresponding Graph/Chart).....III-2
1$200
   Public Sector Funding.....III-3 1$75
   Table 10: National Nanotechnology Initiative Budget in US$ Million by Agency (2015-2017) (includes corresponding Graph/Chart).....III-41$200
   Connecticut – A Key Region with Focus on Nanomedicine.....III-5
Patent Activity in Nanomedicine Domain.....III-5
Major Nanobiotechnology Institutions and Centers.....III-5
The Nanobiotechnology Center (NBTC).....III-5
1$75
   Key Technological Advances Achieved by NBTC.....III-6
Principal NBTC Partners.....III-6
1$75
   Michigan Nanotechnology Institute for Medicine and Biological Sciences
  (MNIMBS).....III-7
Centers of Cancer Nanotechnology Excellence (CCNEs).....III-7
Regulatory Environment.....III-7
1$75
   FDA’s Regulatory Approach to Nanotechnology Products.....III-8
The Perils of Current Regulatory Status on Nanostructures.....III-8
1$75
   Few Challenges Faced by FDA.....III-9
Strategic Corporate Developments.....III-9
1$75
   Select Key Players.....III-104$300
   B. Market Analytics.....III-14
Table 11: US Recent Past, Current & Future Analysis for Nanobiotechnology Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-14
1$200
   Table 12: US Historic Review for Nanobiotechnology Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-151$200
   A. Market Analysis.....III-16
Outlook.....III-16
Table 13: R&D Expenditure in Japan (2015): Percentage Breakdown of Expenditure by Industrial Sector for Energy, Environmental S&T, ICTs, Life sciences, Materials, Nanotechnology, and Others (includes corresponding Graph/Chart).....III-16
1$200
   Nanomedicines in Japan – An Overview.....III-17
List of Select Nanomedicines Approved in Japan.....III-17
Regulations on Nanomedicine in Japan.....III-17
1$75
   B. Market Analytics.....III-18
Table 14: Japanese Recent Past, Current & Future Analysis for Nanobiotechnology Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-18
1$200
   Table 15: Japanese Historic Review for Nanobiotechnology Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-191$200
   A. Market Analysis.....III-20
The Rise of Nanobiotechnology in Europe.....III-20
EU Gears Up for Clarity on Nanomedicine Regulations.....III-20
Market Overview.....III-20
1$75
   Nano2Life Network.....III-21
Public Sector Funding.....III-21
Regulatory Environment.....III-21
1$75
   Registration for Novel Nanobiotech Drugs Pose Major Bottlenecks.....III-22
A Snapshot of Nanotherapeutic Products in the EU.....III-22
List of Select Oral Nanotherapeutic Products.....III-22
1$75
   List of Select Nanotherapeutic Products for Parenteral Administration.....III-23
List of Select Nanotherapeutic Products for Parenteral Administration in the
  EU.....III-23
1$75
   Focus on Select Markets.....III-24
Germany.....III-24
1$75
   A Regional Hub for Nanomedicine Research.....III-25
France.....III-25
1$75
   Nanotechnology and Nanomedicine – An Overview.....III-26
Regulations on Nanomaterials.....III-26
United Kingdom.....III-26
1$75
   UK Bets on Advancing Nanotechnology.....III-27
Russia.....III-27
1$75
   Russian Biotech Players Eye Partnerships with Indian Counterparts.....III-28
Rest of Europe.....III-28
1$75
   Ireland.....III-29
Market Overview.....III-29
Key Research Institutions/Centers in Nanobiotechnology.....III-29
The Tyndall National Institute.....III-29
The Centre for Research on Adaptive Nanostructures and NanoDevices.....III-29
1$75
   The National Centre for Sensor Research.....III-30
Strategic Corporate Developments.....III-30
Select Key Players.....III-30
3$225
   B. Market Analytics.....III-33
Table 16: European Recent Past, Current & Future Analysis for Nanobiotechnology Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-33
1$200
   Table 17: European Historic Review for Nanobiotechnology Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-341$200
   A. Market Analysis.....III-35
Public Sector Funding.....III-35
Focus on Select Markets.....III-35
Australia.....III-35
Market Overview.....III-35
1$75
   Major Institutions.....III-36
Commonwealth Scientific and Industrial Research Organisation (CSIRO).....III-36
China.....III-36
New Findings Reinforce Role of Silica Nanoparticles in Drug Delivery and
  Diagnostics.....III-36
1$75
   Nanotechnology Patent Profile in China.....III-37
India.....III-37
Market Overview.....III-37
Nanotechnology to Spur Indian Pharmaceutical Industry.....III-37
1$75
   Government Takes Big Initiatives to Promote Nanobiotechnology.....III-38
Agriculture, Livestock Sectors to Warm Up to Nanobiotechnology Benefits.....III-38
1$75
   South Korea.....III-39
Taiwan.....III-39
1$75
   Nanotechnology in Medicine – Small Yet Growing Segment in Taiwan.....III-40
Iran.....III-40
1$75
   Strategic Corporate Development.....III-41
Starpharma Holdings Ltd. – A Major Australian Player.....III-41
1$75
   B. Market Analytics.....III-42
Table 18: Rest of World Recent Past, Current & Future Analysis for Nanobiotechnology Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-42
1$200
   Table 19: Rest of World Historic Review for Nanobiotechnology Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-431$200
  
Total Companies Profiled: 79

Region/Country Players

The United States 49 Canada 2 Japan 1 Europe 19 France 2 Germany 6 The United Kingdom 4 Rest of Europe 7 Asia-Pacific (Excluding Japan) 5 Middle East 3
Click here to request a full table of contents and more details on this project.